The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Ryan Zander; Weiguo Cui

doi:10.1080/21645515.2017.1345833

The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Ryan Zander, Weiguo Cui^*

^*Corresponding author for this work

Pathology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.

Original language	English (US)
Pages (from-to)	2269-2271
Number of pages	3
Journal	Human Vaccines and Immunotherapeutics
Volume	13
Issue number	10
DOIs	https://doi.org/10.1080/21645515.2017.1345833
State	Published - Oct 3 2017

Keywords

engineered adoptive cell therapy
pathogen-boosted vaccination

ASJC Scopus subject areas

Immunology and Allergy
Pharmacology
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/21645515.2017.1345833

Cite this

@article{2ff0565f8a9f4460ba47b9691787caea,

title = "The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors",

abstract = "Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.",

keywords = "engineered adoptive cell therapy, pathogen-boosted vaccination",

author = "Ryan Zander and Weiguo Cui",

note = "Funding Information: This work is supported by NIH grants AI125741 (W. C.), 5T32HL007209 (R. Z.). Publisher Copyright: {\textcopyright} 2017 Taylor & Francis.",

year = "2017",

month = oct,

day = "3",

doi = "10.1080/21645515.2017.1345833",

language = "English (US)",

volume = "13",

pages = "2269--2271",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Landes Bioscience",

number = "10",

}

TY - JOUR

T1 - The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

AU - Zander, Ryan

AU - Cui, Weiguo

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.

AB - Recent advancements in adoptive cell therapy (ACT) are opening up new frontiers for cancer immunotherapy. CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. Despite these clinical successes, as well as significant breakthroughs in T cell engineering, the treatment of solid tumors with ACT remains a relentless challenge. Thus, the current consensus of the field is that an urgent need exists for the design of innovative approaches that can improve the efficacy of ACT in treating solid cancers while maintaining a high degree of reliability and safety.

KW - engineered adoptive cell therapy

KW - pathogen-boosted vaccination

UR - http://www.scopus.com/inward/record.url?scp=85031923440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031923440&partnerID=8YFLogxK

U2 - 10.1080/21645515.2017.1345833

DO - 10.1080/21645515.2017.1345833

M3 - Comment/debate

C2 - 28708956

AN - SCOPUS:85031923440

SN - 2164-5515

VL - 13

SP - 2269

EP - 2271

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 10

ER -

The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this